BioAtla, Inc.
BCAB · OTC · United States
Share price · BCAB
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when BCAB's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 28 Aug 2026-44.7%
- 14 Aug 2026-10.4%
Nothing announced by BCAB that day or the session before.
- 7 Jul 2026-10.9%
Nothing announced by BCAB that day or the session before.
- 20 Apr 2026+24.0%
Nothing announced by BCAB that day or the session before.
- 26 Feb 2026+24.1%
Nothing announced by BCAB that day or the session before.
- 2 Feb 2026-35.7%
- 31 Dec 2025-20.8%
- 21 Nov 2025-25.1%
- 18 Nov 2025+19.6%
Nothing announced by BCAB that day or the session before.
- 17 Nov 2025+29.1%
Nothing announced by BCAB that day or the session before.
Share of unusual movement by asset
For each asset, the share of BCAB's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Ozuriftamab vedotinevents and moves
| 2 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 2% |
| Other company news (earnings, financing, releases naming no asset) | — | 32% |
| Sessions with no dated event | — | 67% |
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | CTLA-4Biologic (subtype unspecified) | Non-Small Cell Lung CancerMelanoma | |
| Phase 2 | AXLAntibody–drug conjugate | Non-Small Cell Lung CancerSoft Tissue Sarcoma | |
| Phase 2 | ROR2Antibody–drug conjugate | Non-Small Cell Lung CancerHead and Neck Squamous Cell Carcinoma |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $3.3M | $1.5M | —-$0.4M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | — | $4.6M | $2.0M | $6.3M-$5.3M operating cash flow | report ↗ |
| 2025-Q3 | — | $9.5M | $8.3M | $16M-$9.9M operating cash flow | report ↗ |
| 2025-Q2 | — | $14M | $18M | $19M-$14M operating cash flow | report ↗ |
| 2025-Q1 | — | $12M | $32M | $15M-$16M operating cash flow | report ↗ |
| 2024-Q3 | — | $16M | $57M | $11M-$5.1M operating cash flow | report ↗ |
| 2024-Q2 | — | $16M | $62M | $21M-$19M operating cash flow | report ↗ |
| 2024-Q1 | — | $19M | $81M | $23M-$31M operating cash flow | report ↗ |
| 2023-Q3 | $0 | $28M | $141M | $33M-$27M operating cash flow | report ↗ |
| 2023-Q2 | $0 | $31M | $169M | $36M-$24M operating cash flow | report ↗ |
| 2023-Q1 | $0 | $22M | $193M | $27M-$23M operating cash flow | report ↗ |
| 2022-Q3 | $0 | $20M | $178M | $26M-$24M operating cash flow | report ↗ |
| 2022-Q2 | $0 | $21M | $202M | $29M-$17M operating cash flow | report ↗ |
| 2022-Q1 | $0 | $17M | $219M | $24M-$25M operating cash flow | report ↗ |
| 2021-Q3 | — | $17M | $270M | $23M-$13M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $44M | $7.1M | $15M-$48M operating cash flow | report ↗ |
BioAtla reported collaboration and other revenue of $2.0M for the full year 2025, down from $11.0M in 2024, with R&D spend of $43.57M, down 31.0% YoY from $63.1M. Cash and cash equivalents stood at $7.1M, and the company reported a net loss of $59.6M, compared to a net loss of $69.8M in 2024.
Management initiated a formal process to explore strategic options, including asset sales, licensing, or partnerships, and engaged Tungsten Advisors as exclusive financial advisor, while implementing a workforce reduction and other cost-containment measures. The company expects R&D and G&A expenses to decline in 2026 and continues to conduct the Phase 1 study of BA3182 in adenocarcinomas, with ozuriftamab vedotin in Phase 3 for OPSCC and other candidates in earlier-stage development.
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-08-31 | Vasquez Christian · Chief Financial Officer | Tax withholding | 71 | $1.69 | $120 | Form 4 |
| 2026-08-31 | SHORT JAY M PHD · director, Chief Executive Officer | Tax withholding | 259 | $1.69 | $438 | Form 4 |
| 2026-08-31 | Sievers Eric · Chief Medical Officer | Tax withholding | 134 | $1.69 | $226 | Form 4 |
| 2026-05-31 | Sievers Eric · Chief Medical Officer | Tax withholding | 134 | $3.93 | $527 | Form 4 |
| 2026-05-31 | SHORT JAY M PHD · director, Chief Executive Officer | Tax withholding | 259 | $3.93 | $1K | Form 4 |
| 2026-05-31 | Vasquez Christian · Chief Financial Officer | Tax withholding | 82 | $3.93 | $322 | Form 4 |
| 2026-03-12 | SHORT JAY M PHD · director, Chief Executive Officer | Tax withholding | 639 | $0.17 | $107 | Form 4 |
| 2026-03-11 | Sievers Eric · Chief Medical Officer | Tax withholding | 360 | $0.17 | $61 | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 2 reporting institutions held 0.3M shares ($46K).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | MARSHALL WACE, LLP | 277,630 | $44K |
| 2 | SBI Securities Co., Ltd. | 11,124 | $2K |